268 completed, 98 unknown, 65 recruiting, 36 terminated. 542 Phase 3, 62 Phase 2.
Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil - Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 320 | 2026-10-01 | 2026-09-04 |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu - Gastroesophageal Adenocarcinoma | Phase 3 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 244 | 2026-09-01 | 2026-08-18 |
| A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab - Advanced Colorectal Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 300 | 2026-08-28 | 2026-09-10 |
| Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature Oxaliplatin, Irinotecan, Folinic acid - Pancreatic Ductal Adenocarcinoma | Phase 3 | Recruiting | John Neoptolemos | 394 | 2026-08-17 | 2026-08-27 |
| FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab - Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 270 | 2026-07-30 | 2026-07-27 |
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer ASP2138, Pembrolizumab, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 570 | 2026-07-28 | 2026-10-22 |
| Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old FOLFOX4s, Short Course Radiotherapy - Locally Advanced Rectal Adenocarcinoma | Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-24 | 2026-07-24 |
| A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure BL-M07D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 398 | 2026-07-07 | 2026-07-24 |
| Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers mFOLFOX regimen, Mitazalimab - Biliary Tract Cancer (BTC) | Phase 2 / Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-01 | 2026-02-27 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 538 | 2026-06-29 | 2026-07-24 |
| A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 90 | 2026-06-09 | 2026-07-16 |
| Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer Mitomycin (MM), FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Cytoreductive surgery - Locally Advanced Colorectal Cancer | Phase 3 | Recruiting | Maimónides Biomedical Research Institute of Córdoba | 1083 | 2026-05-26 | 2026-06-08 |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
Showing 20 of 542. Sign in to see all of them.
Colorectal Neoplasms (146) · Colonic Neoplasms (78) · Rectal Neoplasms (67) · Breast Neoplasms (63) · Stomach Neoplasms (44) · Pancreatic Neoplasms (38) · Squamous Cell Carcinoma of Head and Neck (29) · Esophageal Neoplasms (27) · Head and Neck Neoplasms (25) · Neoplasm Metastasis (25) · Carcinoma, Hepatocellular (21) · Esophageal Squamous Cell Carcinoma (20) · Adenocarcinoma Of Esophagus (18) · Parkinson Disease 4, Autosomal Dominant Lewy Body (15) · Nasopharyngeal Carcinoma (14)
Sun Yat-sen University (34) · National Cancer Institute (NCI) (18) · Merck Sharp & Dohme LLC (17) · European Organisation for Research and Treatment of Cancer - EORTC (16) · UNICANCER (15) · Alliance for Clinical Trials in Oncology (14) · Sanofi (13) · Fudan University (12) · Hoffmann-La Roche (11) · Medical Research Council (9) · Federation Francophone de Cancerologie Digestive (8) · Gruppo Oncologico del Nord-Ovest (8) · NSABP Foundation Inc (7) · Bristol-Myers Squibb (6) · Pfizer (6)
United States (170) · China (150) · Germany (109) · France (105) · United Kingdom (103) · Italy (100) · Canada (86) · Spain (83) · Belgium (68) · South Korea (61) · Australia (60) · Japan (56) · Poland (54) · Brazil (51) · Taiwan (50)
Norman Wolmark, MD (6) · Alfredo Falcone, MD (4) · Ming Shi, MD (4) · Raimund Jakesz, MD (4) · Aimery de Gramont, MD (3) · Al B. Benson, MD, FACP (3) · Claus-Henning Koehne, MD (3)
PMID 36306483, PMID 31268130, PMID 21997132, PMID 33356421, PMID 40207789, PMID 33439695, PMID 37139963, PMID 20797891, PMID 23265711, PMID 26861604, PMID 27722750, PMID 28006055, PMID 30293873, PMID 30679026, PMID 31070690, PMID 31378656, PMID 31811950, PMID 32085892, PMID 32418078, PMID 32816630, PMID 33684371, PMID 34037241, PMID 34795131, PMID 35594613, PMID 35623069, PMID 36525610, PMID 38315963, PMID 40341124, PMID 40373876, PMID 41252656, PMID 10076721, PMID 10076722, PMID 10458221, PMID 10550154, PMID 10663329, PMID 11098486, PMID 11391598, PMID 11560968, PMID 11870157, PMID 11913730, PMID 11981766, PMID 12047964, PMID 12049862, PMID 12204666, PMID 12372721, PMID 12490681, PMID 12525193, PMID 12540794, PMID 12782596, PMID 12804433
2023 (10), 2018 (9), 2025 (8), 2015 (7), U10CA031946 (7), U10CA180868 (7), 2016 (6), 2017 (6), U10CA021115 (6), U10CA032102 (6), U10CA012027 (5), U10CA180820 (5), 2019 (4), U10CA180821 (4), 2014 (3)